Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 56.45

-3.0%

1:55 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Ian@SI	5/26/2005 5:10:47 PM
	Read Replies (1) of 52153

Alkermes (ALKS) : Lazard Freres initiates BUY. Target $19. Firm says that substantial intellectual property, increasingly sophisticated formulation, and manufacturing expertise suggest a biotech co more than a specialty pharma. Firm thinks CY05 should witness meaningful clinical progress across multiple products, including Vivitrex (alcohol dependence), AIR Insulin, and Exenatide LAR. +++++++++++++++++++++++++++++++++++++++++++++++ Repligen (RGEN) : Rodman & Renshaw upgrades Mkt Perform to MKT OUTPERFORM. Target $4.50. Rodman & Renshaw upgrades following the co's announcement yesterday on the improving performance of core, marketed products. Firm believes the market fairly values these assets, but appears to ignore RGEN's pipeline, plans for in licensing additional candidates and the potential cash infusion related to settlements of IP disputes. They believe RGEN's current pipeline could be valued at a 50% discount to the average of early to mid-stage development companies (~$50 mln), and think the co's marketed products represent a ~$55 mln value (5x forward revenue multiple).

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next